ARS Pharmaceuticals Company Insiders

ARS Pharmaceuticals Management Team Effectiveness

The company has return on total asset (ROA) of (0.1922) % which means that it has lost $0.1922 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4592) %, meaning that it created substantial loss on money invested by shareholders. ARS Pharmaceuticals' management efficiency ratios could be used to measure how well ARS Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, ARS Pharmaceuticals' Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to rise to 0.02 in 2026, despite the fact that Return On Capital Employed is likely to grow to (0.01). At this time, ARS Pharmaceuticals' Return On Assets are fairly stable compared to the past year. Common Stock Shares Outstanding is likely to rise to about 123.6 M in 2026, despite the fact that Net Loss is likely to grow to (29.7 M). ARS Pharmaceuticals holds a total of 98.85 Million outstanding shares. The majority of ARS Pharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in ARS Pharmaceuticals to benefit from reduced commissions. Therefore, institutional investors are subject to a different set of regulations than regular investors in ARS Pharmaceuticals. Please pay attention to any change in the institutional holdings of ARS Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Also note that nearly four million one hundred two thousand two hundred seventeen invesors are currently shorting ARS Pharmaceuticals expressing very little confidence in its future performance. Some institutional investors establish a significant position in stocks such as ARS Pharmaceuticals in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of ARS Pharmaceuticals, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

ARS Pharmaceuticals Workforce Comparison

ARS Pharmaceuticals Profit Margins

The company has Profit Margin (PM) of (0.56) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.64) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.64.

ARS Pharmaceuticals Insider Trading History

ARS Pharmaceuticals Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as ARS Pharmaceuticals often depends on how effective the management is. ARS Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of ARS management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the ARS management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in ARS Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of ARS Pharmaceuticals. Check ARS Pharmaceuticals' Beneish M Score to see the likelihood of ARS Pharmaceuticals' management manipulating its earnings.

When running ARS Pharmaceuticals' price analysis, check to measure ARS Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ARS Pharmaceuticals is operating at the current time. Most of ARS Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ARS Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ARS Pharmaceuticals' price. Additionally, you may evaluate how the addition of ARS Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.